4basebio UK Societas Notice of AGM and Posting of Accounts

 
TIDM4BB 
 
4basebio UK Societas 
 
                                (the "Company") 
 
                       Notice of Annual General Meeting 
 
               Posting of Annual Report and Financial Statements 
 
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of gene therapies and vaccines, 
confirms that the Annual Report and Accounts for the year ended 30 December 
2020, and the Notice of Annual General Meeting ("AGM") with accompanying Form 
of Proxy has been posted to shareholders today. 
 
These documents are also available, in electronic form, for download on the 
Company's website: https://www.4basebio.com/investors/. 
 
The Company's AGM will be held at 09:00 a.m. on Wednesday, 30 June 2021 at the 
Company's offices at 25 Norman Way, Over, CB24 5QE. This will be followed by a 
presentation from the Company through the Investor Meet Company platform on 1 
July 2021 at 10am. Investors can sign up to Investor Meet Company for free and 
register interest here: https://www.investormeetcompany.com/ 
4basebio-uk-societas/register-investor 
 
The Company continues to monitor developments relating to the outbreak of 
COVID-19, including the related public health guidance and legislation issued 
by the UK Government as well as the "roadmap out of lockdown" published on 22 
February 2021.  At present, it is expected that it will be possible to hold a 
physical AGM and to welcome the maximum number of shareholders we are able 
within safety constraints and in accordance with government guidelines that 
will apply at the time. 
 
However, given the constantly evolving nature of the situation, we want to 
ensure that we are able to adapt these arrangements efficiently to respond to 
changes in circumstances. On this basis, should the situation change such that 
we consider that it is no longer possible for shareholders to attend the 
meeting, we will adopt contingency plans and notify shareholders of the change 
via an RNS announcement as early as is possible before the date of the 
meeting.  Such contingency plans are likely to result in the holding of a 
virtual or hybrid meeting.  Any updates to the position will also be included 
on our website at https://www.4basebio.com/investors/. Should we have to change 
the arrangements in this way, it is likely that we will not be in a position to 
accommodate shareholders beyond the minimum required to hold a quorate meeting 
which will be achieved through the attendance of employee shareholders. 
 
Shareholders intending to attend the AGM, should this be possible, are asked to 
register their intention as soon as practicable (and the Company strongly 
encourages them to advise the Company at least 48 hours in advance of the 
meeting) by emailing the Company Secretary at [e-mail]. Any such 
communication shall not provide a guarantee that admittance to the AGM will be 
permitted where to do so would be in breach of rules governing public 
gatherings and/or the need to protect the health and safety of those already in 
the meeting. 
 
Given the uncertainty around whether shareholders will be able to attend the 
AGM because of tighter restrictions due to a change in the situation with the 
COVID-19 pandemic, we encourage all shareholders to complete and return the 
accompanying Form of Proxy appointing the Chair of the meeting as their proxy 
(or appoint the Chair as their proxy through CREST). This will ensure that your 
vote will be counted if ultimately you (or any other proxy you might otherwise 
appoint) are not able to attend the meeting. 
 
For further enquiries, please contact: 
 
4basebio UK Societas                                       [phone] 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                    [phone] 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                       [phone] 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
Walbrook PR                                             [phone] or 
                                                       [e-mail] 
 
Anna Dunphy / Paul McManus          Mob: [phone] 
                                                                           893 
 
 
Notes to Editors 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for gene therapies and DNA vaccines and providing solutions for effective 
and safe delivery of these DNA based products to patients. It is the intention 
of the Company to become a market leader in the manufacture and supply of high 
purity, synthetic DNA for research, therapeutic and pharmacological use. The 
immediate objectives of 4bb are to validate and scale its DNA synthesis and 
advance its collaborations to facilitate the functional validation of its DNA 
based products and gene delivery solutions. 
 
The Company divested from 4basebio AG ("4bb AG"), a German company listed on 
the Prime Standard segment of the Frankfurt Stock Exchange, following the 
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology 
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the 
disposal, 4bb AG retained its genomics business which owned and licensed 
certain intellectual property including its proprietary, patent-protected 
technology, TruePrimeT. This is the foundation for building the Company's 
synthetic DNA manufacturing business which 4bb AG transferred to the Company 
along with funding to continue the Company's development and investment. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

June 04, 2021 02:00 ET (06:00 GMT)